Intercell AG

EANS-News: Intercell AG
Intercell's partner Biological E. Ltd. launches Japanese Encephalitis vaccine JEEV® in India

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information

Wien (euro adhoc) - << Novel vaccine to protect children and adults from
Japanese Encephalitis (JE), manufactured by partner Biological E. Ltd. is now
available in India

<< Important milestone towards introduction of vaccine based on Intercell's
modern, cell culture-derived technology in endemic countries 

Vienna (Austria)/ Hyderabad (India), September 13, 2012 - Intercell AG (VSE:
ICLL) today announced that its partner Biological E. Ltd. launched the product
JEEV® - a vaccine to protect children and adults from Japanese Encephalitis (JE)
- in India. The vaccine, manufactured by Biological E. Ltd. at its facility in
Hyderabad and based on Intercell's technology was approved by the Drugs
Controller General of India (DCGI). 

"With the market launch in India we have taken a major step forward in achieving
our goal of rolling-out this Japanese Encephalitis vaccine in endemic countries
with a high medical need in order to protect children and adults against this
terrible disease. Our strategic partnership with Biological E. has made this
possible. Now, we will continue to fight against this disease and collaborate on
increasing market penetration in the endemic region", states Thomas Lingelbach,
Chief Executive Officer of Intercell AG. 

Japanese Encephalitis is endemic in Asia and Southeast Asia, a region with more
than 3 billion inhabitants. In 2005, an epidemic outbreak of Japanese
Encephalitis in Uttar Pradesh, India, and Nepal killed more than 1,200 children.

Biological E. plans to focus its sales efforts of JEEV® initially on private
market customers including pediatricians and general practitioners. To ensure a
successful product launch, Biological E. has recruited and trained its own sales
force, which will initially be fully dedicated to the product.
According to the product label, the initial approval age groups of the vaccine
are children (>=1 - <3 years of age) and adults (>=18 - <=49 years of age).
First deliveries of JEEV® are planned between mid-September and beginning of
October, with full scale commercial manufacturing commencing shortly thereafter.

Dr. Vijay Kumar Datla, Chairman & Managing Director of Biological E. said: "With
the launch of JEEV®, the indigenous vaccine with excellent safety profile and
proven efficacy in Indian subjects is now available to doctors for prevention of
Japanese Encephalitis in children and adults."

Biological E. has submitted the Product Summary File under the WHO
Prequalification process and the same is under review. 

The vaccine's further regulatory approval route for other Asian territories is
expected through the World Health Organization - Novartis will be responsible
for the marketing and distribution in these countries. Following the approval
and launch of Intercell's vaccine against Japanese Encephalitis for adult
travelers and military personnel in Europe, the United States, Canada, Hong
Kong, Singapore, Israel (IXIARO®) and Australia (JESPECT®) the development of a
vaccine to protect children and adults in endemic areas from Japanese
Encephalitis has been a major goal of the Company.

In 2005, Intercell and Biological E. signed a contract for the development,
manufacturing, marketing and distribution in India and the Indian subcontinent
of Intercell's Japanese Encephalitis vaccine.

Further inquiry note:
Intercell AG
Nina Waibel
Corporate Communications
Tel. +43 1 20620-1222

end of announcement                               euro adhoc 

company:     Intercell AG
             Campus Vienna Biocenter  3
             A-1030 Wien 
phone:       +43 1 20620-0
FAX:         +43 1 20620-800
sector:      Biotechnology
ISIN:        AT0000612601
indexes:     ATX Prime
stockmarkets: official market: Wien 
language:   English

Weitere Meldungen: Intercell AG

Das könnte Sie auch interessieren: